| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 141 | 2023 | 1226 | 11.990 |
Why?
|
| Oncogene Proteins | 33 | 2015 | 749 | 1.730 |
Why?
|
| L-Lactate Dehydrogenase | 6 | 2020 | 424 | 1.460 |
Why?
|
| Bone Marrow Neoplasms | 4 | 2020 | 104 | 1.370 |
Why?
|
| Gene Amplification | 29 | 2022 | 1063 | 1.350 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 51 | 2023 | 11524 | 1.150 |
Why?
|
| Ganglioneuroma | 4 | 2020 | 57 | 1.070 |
Why?
|
| Infant | 127 | 2023 | 35122 | 1.040 |
Why?
|
| Disease-Free Survival | 61 | 2023 | 6895 | 0.980 |
Why?
|
| Ganglioneuroblastoma | 4 | 2018 | 10 | 0.920 |
Why?
|
| Child, Preschool | 116 | 2023 | 40964 | 0.910 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 20 | 2024 | 5445 | 0.910 |
Why?
|
| Nuclear Proteins | 36 | 2019 | 5854 | 0.900 |
Why?
|
| Pyruvate Kinase | 5 | 2021 | 189 | 0.770 |
Why?
|
| Child | 138 | 2024 | 77637 | 0.740 |
Why?
|
| Ferritins | 5 | 2021 | 590 | 0.720 |
Why?
|
| Prognosis | 63 | 2023 | 29052 | 0.680 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 7 | 2023 | 902 | 0.680 |
Why?
|
| Pyruvate Metabolism, Inborn Errors | 4 | 2021 | 45 | 0.670 |
Why?
|
| Nomograms | 1 | 2020 | 228 | 0.660 |
Why?
|
| Neoplasm Staging | 51 | 2023 | 11036 | 0.660 |
Why?
|
| Anemia, Hemolytic, Congenital Nonspherocytic | 4 | 2021 | 51 | 0.660 |
Why?
|
| Topotecan | 5 | 2011 | 137 | 0.610 |
Why?
|
| Neoplasm Recurrence, Local | 16 | 2023 | 9239 | 0.550 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 6 | 2018 | 272 | 0.520 |
Why?
|
| Information Storage and Retrieval | 1 | 2021 | 824 | 0.510 |
Why?
|
| Cyclophosphamide | 13 | 2023 | 2241 | 0.510 |
Why?
|
| Isotretinoin | 6 | 2021 | 114 | 0.500 |
Why?
|
| Adolescent | 94 | 2023 | 85729 | 0.490 |
Why?
|
| Interleukin-2 | 6 | 2022 | 1904 | 0.480 |
Why?
|
| Graft vs Host Disease | 7 | 2024 | 2958 | 0.480 |
Why?
|
| Neoplasms, Second Primary | 5 | 2023 | 1063 | 0.450 |
Why?
|
| Age Factors | 21 | 2021 | 18355 | 0.430 |
Why?
|
| Information Dissemination | 1 | 2021 | 1099 | 0.420 |
Why?
|
| Proto-Oncogene Proteins c-myc | 6 | 2016 | 988 | 0.400 |
Why?
|
| Anemia, Sickle Cell | 4 | 2023 | 1020 | 0.400 |
Why?
|
| Humans | 230 | 2024 | 743811 | 0.400 |
Why?
|
| Survival Analysis | 31 | 2021 | 10251 | 0.390 |
Why?
|
| Neoplasm Proteins | 4 | 2020 | 3706 | 0.390 |
Why?
|
| Genes, myc | 10 | 2015 | 399 | 0.390 |
Why?
|
| Hodgkin Disease | 8 | 2014 | 1415 | 0.380 |
Why?
|
| Survival Rate | 34 | 2020 | 12786 | 0.380 |
Why?
|
| Bone Neoplasms | 6 | 2019 | 2529 | 0.370 |
Why?
|
| Antineoplastic Agents | 20 | 2020 | 13691 | 0.360 |
Why?
|
| Etoposide | 18 | 2018 | 641 | 0.350 |
Why?
|
| 3-Iodobenzylguanidine | 6 | 2023 | 116 | 0.340 |
Why?
|
| Cisplatin | 17 | 2014 | 1662 | 0.340 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2017 | 629 | 0.340 |
Why?
|
| Mitotic Index | 3 | 2020 | 172 | 0.330 |
Why?
|
| Antibodies, Monoclonal | 9 | 2021 | 9272 | 0.320 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2008 | 120 | 0.310 |
Why?
|
| Risk Assessment | 17 | 2023 | 23327 | 0.310 |
Why?
|
| Skin Neoplasms | 7 | 2023 | 5691 | 0.310 |
Why?
|
| Models, Statistical | 3 | 2018 | 5100 | 0.310 |
Why?
|
| Stomatitis | 2 | 2023 | 267 | 0.310 |
Why?
|
| Receptors, KIR | 3 | 2023 | 113 | 0.300 |
Why?
|
| Combined Modality Therapy | 22 | 2023 | 8637 | 0.300 |
Why?
|
| Germinoma | 6 | 2006 | 134 | 0.290 |
Why?
|
| Male | 114 | 2021 | 349776 | 0.290 |
Why?
|
| Cause of Death | 1 | 2017 | 3580 | 0.290 |
Why?
|
| Kaplan-Meier Estimate | 18 | 2016 | 6539 | 0.280 |
Why?
|
| Risk Factors | 48 | 2023 | 72252 | 0.280 |
Why?
|
| Female | 113 | 2021 | 380020 | 0.270 |
Why?
|
| Genetic Association Studies | 5 | 2020 | 2703 | 0.270 |
Why?
|
| Infant, Newborn | 31 | 2022 | 25609 | 0.260 |
Why?
|
| Young Adult | 39 | 2023 | 56392 | 0.260 |
Why?
|
| Chromosomes, Human, Pair 1 | 6 | 2013 | 657 | 0.260 |
Why?
|
| Transplantation, Autologous | 10 | 2023 | 2123 | 0.250 |
Why?
|
| Gene Expression Regulation, Neoplastic | 18 | 2020 | 8430 | 0.250 |
Why?
|
| Mitosis | 3 | 2020 | 1207 | 0.240 |
Why?
|
| Osteosarcoma | 4 | 2018 | 881 | 0.240 |
Why?
|
| Chromosomes, Human, Pair 6 | 3 | 2018 | 380 | 0.240 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2020 | 545 | 0.240 |
Why?
|
| Retrospective Studies | 40 | 2024 | 77410 | 0.230 |
Why?
|
| Multidrug Resistance-Associated Proteins | 3 | 2011 | 106 | 0.230 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 2023 | 131 | 0.220 |
Why?
|
| Loss of Heterozygosity | 7 | 2019 | 684 | 0.220 |
Why?
|
| Neoadjuvant Therapy | 6 | 2019 | 2727 | 0.220 |
Why?
|
| Ploidies | 6 | 2011 | 281 | 0.220 |
Why?
|
| Bleomycin | 11 | 2012 | 512 | 0.210 |
Why?
|
| Stem Cell Transplantation | 8 | 2019 | 1620 | 0.210 |
Why?
|
| Brain Neoplasms | 7 | 2023 | 8856 | 0.210 |
Why?
|
| Cohort Studies | 27 | 2021 | 40545 | 0.210 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2020 | 4033 | 0.210 |
Why?
|
| Carboplatin | 9 | 2018 | 801 | 0.210 |
Why?
|
| Chromosome Aberrations | 9 | 2022 | 1811 | 0.200 |
Why?
|
| Whole-Body Irradiation | 3 | 2023 | 449 | 0.200 |
Why?
|
| Hepatoblastoma | 3 | 2009 | 87 | 0.200 |
Why?
|
| RNA Interference | 4 | 2020 | 2890 | 0.200 |
Why?
|
| Neoplasms | 10 | 2023 | 21675 | 0.200 |
Why?
|
| Adrenal Gland Neoplasms | 5 | 2016 | 740 | 0.200 |
Why?
|
| Eczema | 1 | 2023 | 231 | 0.190 |
Why?
|
| Treatment Outcome | 39 | 2021 | 63042 | 0.190 |
Why?
|
| Myelodysplastic Syndromes | 3 | 2020 | 1352 | 0.190 |
Why?
|
| Glioma | 3 | 2023 | 3401 | 0.190 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 5 | 2008 | 501 | 0.180 |
Why?
|
| Medulloblastoma | 2 | 2023 | 683 | 0.180 |
Why?
|
| Gene Dosage | 3 | 2017 | 1252 | 0.180 |
Why?
|
| gamma-Globins | 1 | 2020 | 95 | 0.180 |
Why?
|
| Follow-Up Studies | 21 | 2021 | 39001 | 0.180 |
Why?
|
| Peripheral Nervous System Neoplasms | 2 | 2014 | 122 | 0.180 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2023 | 3524 | 0.180 |
Why?
|
| Recurrence | 8 | 2023 | 8337 | 0.180 |
Why?
|
| Receptor, trkA | 3 | 2011 | 164 | 0.180 |
Why?
|
| Hexokinase | 1 | 2020 | 124 | 0.180 |
Why?
|
| Pilot Projects | 12 | 2023 | 8316 | 0.170 |
Why?
|
| Bone Marrow Transplantation | 4 | 2014 | 2764 | 0.170 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2018 | 227 | 0.170 |
Why?
|
| Research Subjects | 1 | 2021 | 239 | 0.170 |
Why?
|
| Disease Progression | 10 | 2019 | 13273 | 0.170 |
Why?
|
| Cytomegalovirus Infections | 2 | 2016 | 820 | 0.170 |
Why?
|
| Proportional Hazards Models | 14 | 2021 | 12354 | 0.170 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 5 | 2014 | 1660 | 0.160 |
Why?
|
| Cerebellar Neoplasms | 1 | 2023 | 587 | 0.160 |
Why?
|
| Salvage Therapy | 3 | 2014 | 1275 | 0.160 |
Why?
|
| Polyamines | 1 | 2019 | 120 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 11 | 2015 | 4749 | 0.160 |
Why?
|
| Sunburn | 1 | 2019 | 155 | 0.160 |
Why?
|
| Fetal Hemoglobin | 1 | 2020 | 341 | 0.160 |
Why?
|
| Amifostine | 2 | 2009 | 41 | 0.160 |
Why?
|
| Opsoclonus-Myoclonus Syndrome | 1 | 2017 | 8 | 0.160 |
Why?
|
| Cell Line, Tumor | 19 | 2019 | 16674 | 0.160 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2022 | 3591 | 0.160 |
Why?
|
| Gene Expression | 4 | 2014 | 7793 | 0.150 |
Why?
|
| Medical Oncology | 3 | 2017 | 2267 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 11 | 5 | 2013 | 417 | 0.150 |
Why?
|
| Blood Component Removal | 1 | 2018 | 125 | 0.150 |
Why?
|
| Radiation-Protective Agents | 2 | 2009 | 90 | 0.150 |
Why?
|
| Sunlight | 1 | 2019 | 325 | 0.150 |
Why?
|
| Heterocyclic Compounds | 1 | 2018 | 248 | 0.150 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2021 | 234 | 0.150 |
Why?
|
| Adult | 45 | 2023 | 213889 | 0.150 |
Why?
|
| Doxorubicin | 10 | 2018 | 2234 | 0.150 |
Why?
|
| Genomics | 5 | 2022 | 5714 | 0.150 |
Why?
|
| Genotype | 10 | 2023 | 12944 | 0.150 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2017 | 114 | 0.140 |
Why?
|
| Neoplasm, Residual | 2 | 2020 | 973 | 0.140 |
Why?
|
| Iron Overload | 1 | 2018 | 242 | 0.140 |
Why?
|
| Health Literacy | 1 | 2022 | 414 | 0.140 |
Why?
|
| Anemia, Aplastic | 2 | 2015 | 226 | 0.140 |
Why?
|
| Vincristine | 8 | 2012 | 1039 | 0.140 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2017 | 323 | 0.140 |
Why?
|
| Homeopathy | 1 | 1995 | 25 | 0.140 |
Why?
|
| Survivors | 3 | 2016 | 2291 | 0.130 |
Why?
|
| Immunotherapy | 5 | 2023 | 4437 | 0.130 |
Why?
|
| Pyrazoles | 3 | 2021 | 1970 | 0.130 |
Why?
|
| Age of Onset | 3 | 2015 | 3268 | 0.130 |
Why?
|
| Disabled Children | 1 | 2018 | 247 | 0.130 |
Why?
|
| Data Interpretation, Statistical | 1 | 2005 | 2715 | 0.130 |
Why?
|
| Dermatitis, Phototoxic | 1 | 2014 | 15 | 0.130 |
Why?
|
| RNA, Small Interfering | 5 | 2020 | 3504 | 0.130 |
Why?
|
| Lymph Nodes | 2 | 2019 | 3476 | 0.130 |
Why?
|
| Gammaretrovirus | 1 | 2014 | 54 | 0.130 |
Why?
|
| X-Linked Combined Immunodeficiency Diseases | 1 | 2014 | 23 | 0.130 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2011 | 1097 | 0.130 |
Why?
|
| Poverty | 3 | 2015 | 2660 | 0.130 |
Why?
|
| Nevus, Pigmented | 1 | 2017 | 219 | 0.130 |
Why?
|
| Remission Induction | 10 | 2014 | 2384 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2014 | 15518 | 0.120 |
Why?
|
| DNA Helicases | 2 | 2012 | 861 | 0.120 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2012 | 1083 | 0.120 |
Why?
|
| Hearing Loss | 2 | 2014 | 765 | 0.120 |
Why?
|
| School Health Services | 1 | 2018 | 375 | 0.120 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2020 | 2110 | 0.120 |
Why?
|
| Prednisone | 2 | 2017 | 1574 | 0.120 |
Why?
|
| Histone Deacetylase 2 | 1 | 2014 | 74 | 0.120 |
Why?
|
| Antifungal Agents | 2 | 2019 | 729 | 0.120 |
Why?
|
| Ependymoma | 1 | 2017 | 334 | 0.120 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2018 | 364 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2019 | 5170 | 0.120 |
Why?
|
| Uterine Hemorrhage | 1 | 2015 | 255 | 0.120 |
Why?
|
| Consensus | 3 | 2018 | 2954 | 0.120 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2014 | 102 | 0.120 |
Why?
|
| Chromosome Deletion | 1 | 2018 | 1396 | 0.120 |
Why?
|
| Topoisomerase I Inhibitors | 2 | 2011 | 65 | 0.120 |
Why?
|
| Melanoma | 2 | 2023 | 5508 | 0.110 |
Why?
|
| Iodine Radioisotopes | 3 | 2013 | 1035 | 0.110 |
Why?
|
| Immunomagnetic Separation | 1 | 2013 | 80 | 0.110 |
Why?
|
| Transplantation Conditioning | 3 | 2023 | 1599 | 0.110 |
Why?
|
| Thoracic Neoplasms | 2 | 2014 | 268 | 0.110 |
Why?
|
| Testicular Neoplasms | 3 | 2004 | 803 | 0.110 |
Why?
|
| Tubulin Modulators | 1 | 2013 | 110 | 0.110 |
Why?
|
| Physician Executives | 1 | 2014 | 128 | 0.110 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2017 | 652 | 0.110 |
Why?
|
| Iron | 2 | 2018 | 1774 | 0.110 |
Why?
|
| Cell Nucleolus | 1 | 2013 | 166 | 0.110 |
Why?
|
| Drug Administration Schedule | 4 | 2019 | 4931 | 0.110 |
Why?
|
| Serine Endopeptidases | 1 | 2018 | 1073 | 0.110 |
Why?
|
| Research Report | 2 | 2013 | 355 | 0.110 |
Why?
|
| Neurofibromatosis 1 | 1 | 2018 | 570 | 0.110 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 1978 | 0.110 |
Why?
|
| Diabetes Insipidus | 1 | 2013 | 151 | 0.110 |
Why?
|
| Neoplasm Metastasis | 9 | 2017 | 4848 | 0.110 |
Why?
|
| Nervous System Neoplasms | 2 | 2009 | 91 | 0.110 |
Why?
|
| DNA-Binding Proteins | 4 | 2016 | 9648 | 0.110 |
Why?
|
| Karyotyping | 1 | 2014 | 1243 | 0.110 |
Why?
|
| RNA, Messenger | 10 | 2012 | 13028 | 0.110 |
Why?
|
| Pelvic Neoplasms | 1 | 2014 | 254 | 0.110 |
Why?
|
| Pediatrics | 3 | 2021 | 3474 | 0.100 |
Why?
|
| Immunohistochemistry | 6 | 2021 | 11360 | 0.100 |
Why?
|
| Pituitary Diseases | 1 | 2013 | 140 | 0.100 |
Why?
|
| Fenretinide | 1 | 2011 | 12 | 0.100 |
Why?
|
| Thymopentin | 1 | 2011 | 1 | 0.100 |
Why?
|
| Receptor, Nerve Growth Factor | 1 | 2011 | 48 | 0.100 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2012 | 225 | 0.100 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2011 | 97 | 0.100 |
Why?
|
| Amenorrhea | 1 | 2015 | 485 | 0.100 |
Why?
|
| Mutation | 9 | 2023 | 29777 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 2504 | 0.100 |
Why?
|
| Razoxane | 2 | 2012 | 44 | 0.100 |
Why?
|
| Gene Expression Profiling | 7 | 2016 | 9440 | 0.100 |
Why?
|
| Camptothecin | 3 | 2017 | 576 | 0.100 |
Why?
|
| Neonatal Screening | 1 | 2016 | 590 | 0.100 |
Why?
|
| Medical Records | 2 | 2015 | 1412 | 0.100 |
Why?
|
| Predictive Value of Tests | 12 | 2015 | 15067 | 0.100 |
Why?
|
| Fever | 2 | 2017 | 1616 | 0.100 |
Why?
|
| Databases, Factual | 4 | 2021 | 7729 | 0.100 |
Why?
|
| Telomerase | 1 | 2016 | 731 | 0.100 |
Why?
|
| Radiopharmaceuticals | 4 | 2017 | 2647 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 12 | 2020 | 17439 | 0.090 |
Why?
|
| Erythrocytes | 1 | 2020 | 2455 | 0.090 |
Why?
|
| Oncogenes | 3 | 2014 | 1265 | 0.090 |
Why?
|
| Time Factors | 14 | 2019 | 40038 | 0.090 |
Why?
|
| Gene Silencing | 3 | 2014 | 1537 | 0.090 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2023 | 3389 | 0.090 |
Why?
|
| MicroRNAs | 3 | 2011 | 3750 | 0.090 |
Why?
|
| Pituitary Gland | 1 | 2013 | 664 | 0.090 |
Why?
|
| DNA Copy Number Variations | 3 | 2018 | 1937 | 0.090 |
Why?
|
| Risk | 7 | 2019 | 9677 | 0.090 |
Why?
|
| Caspase 8 | 2 | 2007 | 195 | 0.090 |
Why?
|
| Gangliosides | 1 | 2010 | 137 | 0.090 |
Why?
|
| Income | 2 | 2015 | 1913 | 0.090 |
Why?
|
| Genetic Vectors | 2 | 2020 | 3421 | 0.090 |
Why?
|
| Repressor Proteins | 1 | 2020 | 3024 | 0.090 |
Why?
|
| Fanconi Anemia | 1 | 2012 | 319 | 0.090 |
Why?
|
| Skin Diseases | 1 | 2018 | 1066 | 0.090 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2015 | 1205 | 0.080 |
Why?
|
| Craniopharyngioma | 1 | 2012 | 281 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 1956 | 0.080 |
Why?
|
| Ornithine Decarboxylase | 1 | 2008 | 63 | 0.080 |
Why?
|
| Transcription Factors | 3 | 2016 | 12209 | 0.080 |
Why?
|
| Prospective Studies | 14 | 2023 | 53250 | 0.080 |
Why?
|
| Intention to Treat Analysis | 3 | 2019 | 426 | 0.080 |
Why?
|
| Ribonuclease III | 1 | 2010 | 275 | 0.080 |
Why?
|
| Nerve Growth Factors | 1 | 2011 | 574 | 0.080 |
Why?
|
| Diarrhea | 1 | 1995 | 1348 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2016 | 2944 | 0.080 |
Why?
|
| Watchful Waiting | 1 | 2012 | 491 | 0.080 |
Why?
|
| Causality | 2 | 2014 | 1275 | 0.080 |
Why?
|
| Tumor Necrosis Factor Decoy Receptors | 1 | 2007 | 9 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 1789 | 0.080 |
Why?
|
| Gene Deletion | 3 | 2013 | 2749 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2009 | 2850 | 0.080 |
Why?
|
| Health Behavior | 1 | 2019 | 2634 | 0.080 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2017 | 1363 | 0.070 |
Why?
|
| Australia | 1 | 2010 | 1167 | 0.070 |
Why?
|
| Abdominal Neoplasms | 3 | 2005 | 292 | 0.070 |
Why?
|
| Age Distribution | 2 | 2010 | 2899 | 0.070 |
Why?
|
| Europe | 2 | 2010 | 3336 | 0.070 |
Why?
|
| North America | 1 | 2010 | 1249 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 2 | 2012 | 4463 | 0.070 |
Why?
|
| Receptors, IgG | 1 | 2010 | 581 | 0.070 |
Why?
|
| Multivariate Analysis | 7 | 2019 | 12243 | 0.070 |
Why?
|
| Ligands | 3 | 2023 | 3281 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2015 | 2251 | 0.070 |
Why?
|
| Japan | 1 | 2010 | 1360 | 0.070 |
Why?
|
| Transfection | 5 | 2014 | 5892 | 0.070 |
Why?
|
| Transplantation, Homologous | 4 | 2022 | 4777 | 0.070 |
Why?
|
| Genetic Variation | 3 | 2014 | 6535 | 0.070 |
Why?
|
| Immunosuppressive Agents | 2 | 2019 | 4152 | 0.070 |
Why?
|
| DNA, Neoplasm | 2 | 2009 | 1758 | 0.070 |
Why?
|
| Ovarian Neoplasms | 4 | 2016 | 4839 | 0.070 |
Why?
|
| Ifosfamide | 3 | 2014 | 228 | 0.070 |
Why?
|
| Membrane Proteins | 3 | 2018 | 7880 | 0.070 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2021 | 841 | 0.070 |
Why?
|
| Chelating Agents | 1 | 2007 | 379 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 6 | 2016 | 6170 | 0.060 |
Why?
|
| Hearing Disorders | 1 | 2005 | 124 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 3917 | 0.060 |
Why?
|
| Referral and Consultation | 1 | 2018 | 3530 | 0.060 |
Why?
|
| Genome-Wide Association Study | 3 | 2014 | 12259 | 0.060 |
Why?
|
| Radionuclide Imaging | 3 | 2015 | 2034 | 0.060 |
Why?
|
| Bone Marrow | 1 | 2015 | 2951 | 0.060 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 3463 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2006 | 623 | 0.060 |
Why?
|
| Maximum Tolerated Dose | 2 | 2021 | 892 | 0.060 |
Why?
|
| Methylation | 1 | 2007 | 1104 | 0.060 |
Why?
|
| Parents | 1 | 2018 | 3403 | 0.060 |
Why?
|
| United States | 9 | 2019 | 69859 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2013 | 1938 | 0.060 |
Why?
|
| Terminal Care | 1 | 2016 | 1694 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 3839 | 0.060 |
Why?
|
| Cell Differentiation | 4 | 2015 | 11478 | 0.060 |
Why?
|
| Leukemia, Myeloid | 1 | 2007 | 707 | 0.060 |
Why?
|
| Italy | 1 | 2005 | 829 | 0.060 |
Why?
|
| Spinal Cord Compression | 1 | 2005 | 234 | 0.060 |
Why?
|
| Probability | 2 | 2007 | 2505 | 0.060 |
Why?
|
| Diploidy | 3 | 2008 | 138 | 0.060 |
Why?
|
| Germany | 1 | 2005 | 862 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 3 | 2014 | 2736 | 0.060 |
Why?
|
| Incidence | 7 | 2016 | 20948 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2023 | 35409 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 5532 | 0.060 |
Why?
|
| Wiskott-Aldrich Syndrome Protein | 1 | 2023 | 160 | 0.050 |
Why?
|
| Down-Regulation | 3 | 2020 | 3000 | 0.050 |
Why?
|
| Pyridines | 1 | 2014 | 2827 | 0.050 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2011 | 895 | 0.050 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 1832 | 0.050 |
Why?
|
| Cell Cycle | 2 | 2020 | 2963 | 0.050 |
Why?
|
| Logistic Models | 5 | 2019 | 13404 | 0.050 |
Why?
|
| Developing Countries | 1 | 2015 | 2815 | 0.050 |
Why?
|
| International Cooperation | 3 | 2015 | 1419 | 0.050 |
Why?
|
| Blotting, Western | 5 | 2015 | 5179 | 0.050 |
Why?
|
| Hematopoiesis | 1 | 2012 | 2073 | 0.050 |
Why?
|
| Capsules | 2 | 2013 | 196 | 0.050 |
Why?
|
| Liver Neoplasms | 3 | 2016 | 4251 | 0.050 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2005 | 287 | 0.050 |
Why?
|
| New England | 2 | 2015 | 1022 | 0.050 |
Why?
|
| Decontamination | 1 | 2022 | 69 | 0.050 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2001 | 90 | 0.050 |
Why?
|
| Urogenital Neoplasms | 1 | 2003 | 137 | 0.050 |
Why?
|
| Cross-Sectional Studies | 6 | 2019 | 25032 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2014 | 2291 | 0.050 |
Why?
|
| Histocompatibility Antigens | 1 | 2023 | 471 | 0.050 |
Why?
|
| Blood Transfusion | 2 | 2018 | 1301 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 4 | 2018 | 4803 | 0.050 |
Why?
|
| Length of Stay | 1 | 2015 | 6311 | 0.050 |
Why?
|
| Recombinant Proteins | 3 | 2021 | 6620 | 0.050 |
Why?
|
| Paclitaxel | 2 | 2008 | 1705 | 0.050 |
Why?
|
| Dacarbazine | 2 | 2017 | 566 | 0.050 |
Why?
|
| Radiotherapy | 3 | 2019 | 1533 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 6237 | 0.050 |
Why?
|
| Sarcoma | 1 | 2012 | 1898 | 0.050 |
Why?
|
| Neutropenia | 3 | 2017 | 895 | 0.050 |
Why?
|
| Palliative Care | 1 | 2016 | 3490 | 0.050 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 1520 | 0.050 |
Why?
|
| Patient Readmission | 1 | 2015 | 3117 | 0.050 |
Why?
|
| Orchiectomy | 1 | 2003 | 468 | 0.050 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2012 | 1733 | 0.050 |
Why?
|
| Busulfan | 1 | 2021 | 263 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 1639 | 0.040 |
Why?
|
| Benzoates | 1 | 2021 | 218 | 0.040 |
Why?
|
| Case-Control Studies | 5 | 2020 | 21733 | 0.040 |
Why?
|
| Hydrazines | 1 | 2021 | 225 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2012 | 2649 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2009 | 1861 | 0.040 |
Why?
|
| GATA2 Transcription Factor | 1 | 2020 | 161 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2016 | 2883 | 0.040 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2003 | 340 | 0.040 |
Why?
|
| Vinblastine | 2 | 2014 | 501 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2009 | 3208 | 0.040 |
Why?
|
| Lung Neoplasms | 2 | 2017 | 13112 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2012 | 437 | 0.040 |
Why?
|
| Molecular Biology | 1 | 2023 | 595 | 0.040 |
Why?
|
| Melphalan | 1 | 2021 | 431 | 0.040 |
Why?
|
| Colony-Forming Units Assay | 2 | 2010 | 355 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2011 | 2945 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2008 | 2453 | 0.040 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2023 | 710 | 0.040 |
Why?
|
| Hepatomegaly | 1 | 2018 | 85 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2010 | 1796 | 0.040 |
Why?
|
| Mice | 10 | 2022 | 81154 | 0.040 |
Why?
|
| Filgrastim | 1 | 2018 | 133 | 0.040 |
Why?
|
| Algorithms | 1 | 2019 | 13869 | 0.040 |
Why?
|
| Platelet Count | 1 | 2021 | 780 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2020 | 876 | 0.040 |
Why?
|
| Monte Carlo Method | 1 | 2023 | 1254 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2001 | 705 | 0.040 |
Why?
|
| Odds Ratio | 4 | 2012 | 9848 | 0.040 |
Why?
|
| Radiometry | 1 | 2023 | 800 | 0.040 |
Why?
|
| Life Tables | 3 | 2004 | 363 | 0.040 |
Why?
|
| DNA Methylation | 2 | 2012 | 4286 | 0.040 |
Why?
|
| Receptors, KIR2DL1 | 1 | 2017 | 15 | 0.040 |
Why?
|
| Biosynthetic Pathways | 1 | 2019 | 137 | 0.040 |
Why?
|
| Receptors, KIR3DL1 | 1 | 2017 | 22 | 0.040 |
Why?
|
| Research Design | 2 | 2022 | 5983 | 0.040 |
Why?
|
| Up-Regulation | 3 | 2014 | 4221 | 0.040 |
Why?
|
| Animals | 14 | 2022 | 168660 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 2942 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2018 | 3701 | 0.040 |
Why?
|
| Urinary Catheterization | 1 | 1999 | 201 | 0.040 |
Why?
|
| Nail Diseases | 1 | 2018 | 51 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2014 | 2617 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2019 | 5078 | 0.040 |
Why?
|
| Illinois | 1 | 2017 | 119 | 0.040 |
Why?
|
| Benzylamines | 1 | 2018 | 223 | 0.040 |
Why?
|
| Macrophages | 1 | 2012 | 5651 | 0.040 |
Why?
|
| Mediastinal Neoplasms | 1 | 2001 | 423 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 2 | 2022 | 2727 | 0.040 |
Why?
|
| Vitiligo | 1 | 2018 | 89 | 0.040 |
Why?
|
| Cell Proliferation | 4 | 2016 | 10477 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2005 | 3617 | 0.040 |
Why?
|
| Prevalence | 3 | 2021 | 15211 | 0.040 |
Why?
|
| Defibrillators, Implantable | 2 | 1998 | 1439 | 0.040 |
Why?
|
| Washington | 1 | 2017 | 314 | 0.040 |
Why?
|
| DNA, Complementary | 2 | 2014 | 2050 | 0.040 |
Why?
|
| Iatrogenic Disease | 1 | 2020 | 546 | 0.040 |
Why?
|
| Urinary Incontinence, Stress | 1 | 1999 | 183 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 7908 | 0.040 |
Why?
|
| Quality of Life | 4 | 2021 | 12788 | 0.040 |
Why?
|
| Cell Movement | 3 | 2016 | 5216 | 0.040 |
Why?
|
| alpha-Fetoproteins | 2 | 2008 | 223 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2017 | 1770 | 0.040 |
Why?
|
| Urethra | 1 | 1999 | 407 | 0.040 |
Why?
|
| Genome, Human | 4 | 2013 | 4418 | 0.040 |
Why?
|
| Splenectomy | 1 | 2018 | 394 | 0.030 |
Why?
|
| Hypokalemia | 1 | 2017 | 153 | 0.030 |
Why?
|
| Genetic Markers | 3 | 2009 | 2634 | 0.030 |
Why?
|
| Isoelectric Focusing | 1 | 2016 | 180 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 1656 | 0.030 |
Why?
|
| Germ Cells | 1 | 2020 | 629 | 0.030 |
Why?
|
| Cholecystectomy | 1 | 2018 | 395 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 1836 | 0.030 |
Why?
|
| Fluorouracil | 3 | 2006 | 1619 | 0.030 |
Why?
|
| Myeloablative Agonists | 1 | 2016 | 218 | 0.030 |
Why?
|
| Mice, Nude | 2 | 2015 | 3680 | 0.030 |
Why?
|
| Liberia | 1 | 2016 | 167 | 0.030 |
Why?
|
| Animals, Genetically Modified | 1 | 2020 | 1552 | 0.030 |
Why?
|
| Ataxia | 1 | 2017 | 304 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 609 | 0.030 |
Why?
|
| DNA Mutational Analysis | 2 | 2018 | 4183 | 0.030 |
Why?
|
| Premedication | 1 | 2016 | 258 | 0.030 |
Why?
|
| Goserelin | 1 | 2015 | 129 | 0.030 |
Why?
|
| Middle Aged | 12 | 2020 | 213241 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2017 | 402 | 0.030 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2014 | 87 | 0.030 |
Why?
|
| Apoptosis | 3 | 2020 | 9718 | 0.030 |
Why?
|
| Cluster Analysis | 2 | 2014 | 2712 | 0.030 |
Why?
|
| Vaginal Smears | 1 | 1997 | 511 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2017 | 593 | 0.030 |
Why?
|
| Cyclohexylamines | 1 | 2014 | 21 | 0.030 |
Why?
|
| Hydrogen Bonding | 1 | 2014 | 291 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2017 | 929 | 0.030 |
Why?
|
| Suspensions | 1 | 2013 | 65 | 0.030 |
Why?
|
| Gene Frequency | 2 | 2012 | 3585 | 0.030 |
Why?
|
| Alopecia | 1 | 2018 | 382 | 0.030 |
Why?
|
| Transplantation, Heterologous | 2 | 2015 | 2378 | 0.030 |
Why?
|
| Contraceptive Agents, Female | 1 | 2015 | 135 | 0.030 |
Why?
|
| Mice, Transgenic | 3 | 2011 | 9731 | 0.030 |
Why?
|
| Spinal Neoplasms | 1 | 2001 | 760 | 0.030 |
Why?
|
| Resuscitation Orders | 1 | 2016 | 269 | 0.030 |
Why?
|
| Leuprolide | 1 | 2015 | 321 | 0.030 |
Why?
|
| Alleles | 3 | 2010 | 6934 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2014 | 5787 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2018 | 1880 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2022 | 1177 | 0.030 |
Why?
|
| Hepatitis Antibodies | 1 | 1993 | 73 | 0.030 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2016 | 314 | 0.030 |
Why?
|
| Obesity | 2 | 2012 | 12744 | 0.030 |
Why?
|
| International Classification of Diseases | 2 | 2008 | 866 | 0.030 |
Why?
|
| Carcinoma | 1 | 2005 | 2375 | 0.030 |
Why?
|
| Membrane Transport Proteins | 1 | 2019 | 1030 | 0.030 |
Why?
|
| Radiography | 2 | 2015 | 7010 | 0.030 |
Why?
|
| International Agencies | 1 | 2013 | 240 | 0.030 |
Why?
|
| Viremia | 1 | 2016 | 736 | 0.030 |
Why?
|
| Central America | 1 | 2012 | 68 | 0.030 |
Why?
|
| Histones | 1 | 2023 | 2598 | 0.030 |
Why?
|
| Ribosomes | 1 | 2016 | 500 | 0.030 |
Why?
|
| Phenotype | 3 | 2018 | 16361 | 0.030 |
Why?
|
| Bone Marrow Diseases | 1 | 2014 | 231 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2014 | 658 | 0.030 |
Why?
|
| Hepatitis E virus | 1 | 1993 | 71 | 0.030 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2016 | 484 | 0.030 |
Why?
|
| Hepatitis E | 1 | 1993 | 76 | 0.030 |
Why?
|
| Fanconi Anemia Complementation Group A Protein | 1 | 2012 | 46 | 0.030 |
Why?
|
| SEER Program | 1 | 2017 | 1507 | 0.030 |
Why?
|
| Cytokines | 1 | 2007 | 7324 | 0.030 |
Why?
|
| Second-Look Surgery | 1 | 2011 | 29 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 9944 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 1787 | 0.030 |
Why?
|
| Carcinoma in Situ | 1 | 1997 | 805 | 0.030 |
Why?
|
| Receptor, trkB | 1 | 2012 | 125 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2020 | 1928 | 0.030 |
Why?
|
| Reproducibility of Results | 5 | 2011 | 19894 | 0.030 |
Why?
|
| Mycoses | 1 | 2014 | 376 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2014 | 913 | 0.020 |
Why?
|
| Boston | 2 | 2014 | 9310 | 0.020 |
Why?
|
| Quality Control | 1 | 2014 | 841 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 15526 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 3175 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2012 | 294 | 0.020 |
Why?
|
| Radiotherapy Dosage | 2 | 2009 | 2879 | 0.020 |
Why?
|
| Transgenes | 1 | 2014 | 1008 | 0.020 |
Why?
|
| Receptors, Eph Family | 2 | 2000 | 44 | 0.020 |
Why?
|
| Receptor, EphB4 | 2 | 2000 | 38 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 10940 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2016 | 1459 | 0.020 |
Why?
|
| Ephrin-B3 | 2 | 2000 | 12 | 0.020 |
Why?
|
| Retinoids | 1 | 2011 | 101 | 0.020 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 147 | 0.020 |
Why?
|
| Adrenalectomy | 1 | 2012 | 342 | 0.020 |
Why?
|
| Drug Resistance, Multiple | 1 | 2011 | 251 | 0.020 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 725 | 0.020 |
Why?
|
| Ephrin-B2 | 2 | 2000 | 39 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 3020 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 1799 | 0.020 |
Why?
|
| Psoriasis | 1 | 2018 | 901 | 0.020 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2014 | 627 | 0.020 |
Why?
|
| Leukemia Virus, Murine | 1 | 1990 | 117 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 498 | 0.020 |
Why?
|
| Sirolimus | 1 | 2017 | 1565 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2012 | 3480 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2010 | 328 | 0.020 |
Why?
|
| Personal Satisfaction | 1 | 2014 | 641 | 0.020 |
Why?
|
| Rhabdomyosarcoma | 1 | 2012 | 384 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2015 | 1917 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 950 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 847 | 0.020 |
Why?
|
| Biogenic Polyamines | 1 | 2008 | 4 | 0.020 |
Why?
|
| Eflornithine | 1 | 2008 | 31 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 2278 | 0.020 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 354 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 1178 | 0.020 |
Why?
|
| Bone Marrow Purging | 1 | 2009 | 109 | 0.020 |
Why?
|
| Zebrafish | 1 | 2020 | 2995 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2010 | 573 | 0.020 |
Why?
|
| Chromosome Breakage | 1 | 2009 | 173 | 0.020 |
Why?
|
| DNA, Antisense | 1 | 2008 | 46 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2017 | 2016 | 0.020 |
Why?
|
| Mass Screening | 2 | 2021 | 5251 | 0.020 |
Why?
|
| Prednisolone | 1 | 2009 | 334 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2010 | 793 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2016 | 19232 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 1503 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2009 | 1374 | 0.020 |
Why?
|
| Organ Size | 1 | 2013 | 2241 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2008 | 399 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 3503 | 0.020 |
Why?
|
| Phosphorylation | 2 | 2014 | 8436 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 2014 | 1009 | 0.020 |
Why?
|
| Anemia | 1 | 2017 | 1502 | 0.020 |
Why?
|
| Disease Management | 1 | 2018 | 2459 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2010 | 769 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2012 | 1081 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2008 | 644 | 0.020 |
Why?
|
| DNA Repair | 1 | 2016 | 2045 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2012 | 1524 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2008 | 496 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 2 | 2009 | 5867 | 0.020 |
Why?
|
| Biopsy | 2 | 2014 | 6750 | 0.020 |
Why?
|
| Sensitivity and Specificity | 3 | 2009 | 14714 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2006 | 6356 | 0.020 |
Why?
|
| Linear Models | 1 | 2017 | 5952 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2012 | 1152 | 0.020 |
Why?
|
| Sympathetic Nervous System | 1 | 2009 | 513 | 0.020 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2007 | 87 | 0.020 |
Why?
|
| Kinetics | 1 | 2014 | 6476 | 0.020 |
Why?
|
| Skin | 1 | 2020 | 4372 | 0.020 |
Why?
|
| Virus Diseases | 1 | 2013 | 711 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 18027 | 0.020 |
Why?
|
| Procarbazine | 1 | 2006 | 181 | 0.020 |
Why?
|
| Mechlorethamine | 1 | 2006 | 136 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2016 | 1859 | 0.020 |
Why?
|
| Genes, MDR | 1 | 2006 | 36 | 0.020 |
Why?
|
| Azacitidine | 1 | 2008 | 347 | 0.020 |
Why?
|
| Tachycardia, Ventricular | 1 | 1995 | 1272 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 2924 | 0.020 |
Why?
|
| Laboratories | 1 | 2010 | 462 | 0.020 |
Why?
|
| Signal Transduction | 3 | 2020 | 23398 | 0.020 |
Why?
|
| Chorionic Gonadotropin | 1 | 2008 | 475 | 0.020 |
Why?
|
| Cystic Fibrosis | 1 | 2014 | 1178 | 0.020 |
Why?
|
| DNA Primers | 1 | 2010 | 2891 | 0.020 |
Why?
|
| Social Support | 1 | 2015 | 2118 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2010 | 1213 | 0.020 |
Why?
|
| Polysomnography | 1 | 2012 | 1776 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1997 | 2018 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2014 | 2483 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2006 | 215 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2014 | 2566 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 1171 | 0.020 |
Why?
|
| Plasmids | 1 | 2010 | 2308 | 0.020 |
Why?
|
| Enzyme Inhibitors | 2 | 2007 | 3794 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2014 | 1775 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2010 | 1382 | 0.020 |
Why?
|
| Massachusetts | 1 | 2017 | 8660 | 0.020 |
Why?
|
| Antibodies | 1 | 2013 | 2459 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2008 | 640 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2008 | 1794 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2014 | 5445 | 0.020 |
Why?
|
| Diagnostic Imaging | 2 | 2011 | 3503 | 0.010 |
Why?
|
| Hospitals | 1 | 2018 | 3953 | 0.010 |
Why?
|
| Fibroblasts | 2 | 2012 | 4162 | 0.010 |
Why?
|
| Research | 1 | 2012 | 1999 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2011 | 3144 | 0.010 |
Why?
|
| Cytarabine | 1 | 2006 | 692 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2016 | 2984 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2011 | 3912 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2009 | 915 | 0.010 |
Why?
|
| Homozygote | 1 | 2008 | 1787 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2006 | 648 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 1995 | 2620 | 0.010 |
Why?
|
| Leucovorin | 1 | 2005 | 628 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2013 | 1619 | 0.010 |
Why?
|
| Caspases | 1 | 2006 | 928 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2012 | 2865 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2006 | 879 | 0.010 |
Why?
|
| Vaginal Neoplasms | 1 | 2003 | 105 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2012 | 2927 | 0.010 |
Why?
|
| Heterozygote | 1 | 2009 | 2803 | 0.010 |
Why?
|
| Protein Binding | 1 | 2014 | 9377 | 0.010 |
Why?
|
| DNA Damage | 1 | 2012 | 2429 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2006 | 690 | 0.010 |
Why?
|
| Pain | 1 | 2017 | 4987 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2012 | 2683 | 0.010 |
Why?
|
| Decision Making | 1 | 2016 | 3887 | 0.010 |
Why?
|
| Cyclin D | 1 | 2001 | 72 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2012 | 4026 | 0.010 |
Why?
|
| Penile Neoplasms | 1 | 2003 | 161 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2009 | 2123 | 0.010 |
Why?
|
| Fetus | 1 | 2009 | 1880 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2005 | 1683 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2010 | 2131 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2008 | 3847 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 7784 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 12066 | 0.010 |
Why?
|
| Biological Transport | 1 | 2005 | 2119 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 6487 | 0.010 |
Why?
|
| Comorbidity | 1 | 2014 | 10380 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 2008 | 1376 | 0.010 |
Why?
|
| Laminectomy | 1 | 2001 | 234 | 0.010 |
Why?
|
| Patient Selection | 1 | 2012 | 4210 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 4326 | 0.010 |
Why?
|
| Paresis | 1 | 2001 | 180 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 2005 | 1041 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 12954 | 0.010 |
Why?
|
| Cyclins | 1 | 2001 | 603 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2001 | 323 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2001 | 381 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2008 | 6457 | 0.010 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2005 | 570 | 0.010 |
Why?
|
| Differential Threshold | 1 | 1998 | 80 | 0.010 |
Why?
|
| Cell Survival | 1 | 2008 | 5881 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2014 | 4687 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2001 | 539 | 0.010 |
Why?
|
| Methotrexate | 1 | 2005 | 1726 | 0.010 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2001 | 671 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 2001 | 705 | 0.010 |
Why?
|
| Antigens, Viral | 2 | 1993 | 1035 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2006 | 2969 | 0.010 |
Why?
|
| Urodynamics | 1 | 1999 | 347 | 0.010 |
Why?
|
| Fiber Optic Technology | 1 | 1999 | 290 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2005 | 6311 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2011 | 20121 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 10179 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2012 | 14563 | 0.010 |
Why?
|
| Registries | 1 | 2012 | 8090 | 0.010 |
Why?
|
| Aged | 5 | 2014 | 163178 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2007 | 1887 | 0.010 |
Why?
|
| Acute Disease | 1 | 2007 | 7150 | 0.010 |
Why?
|
| Cell Line | 2 | 2005 | 15993 | 0.010 |
Why?
|
| Pressure | 1 | 1999 | 1205 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2001 | 685 | 0.010 |
Why?
|
| Automation | 1 | 1997 | 584 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2000 | 2008 | 0.010 |
Why?
|
| Electric Countershock | 1 | 1998 | 534 | 0.010 |
Why?
|
| Fetal Diseases | 1 | 2000 | 903 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2007 | 3645 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 21824 | 0.010 |
Why?
|
| Uterine Neoplasms | 1 | 2003 | 1513 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2007 | 2789 | 0.010 |
Why?
|
| Thyroid Neoplasms | 1 | 2007 | 2282 | 0.010 |
Why?
|
| Moths | 1 | 1993 | 85 | 0.010 |
Why?
|
| Inflammation | 1 | 2012 | 10629 | 0.010 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2000 | 1695 | 0.010 |
Why?
|
| Primates | 1 | 1993 | 545 | 0.010 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1995 | 788 | 0.010 |
Why?
|
| Base Sequence | 2 | 1993 | 12798 | 0.010 |
Why?
|
| AIDS-Related Complex | 1 | 1990 | 110 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 1993 | 811 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2001 | 4552 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1990 | 829 | 0.010 |
Why?
|
| RNA | 1 | 1999 | 2748 | 0.010 |
Why?
|
| Forecasting | 1 | 1998 | 2950 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1993 | 18107 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1993 | 4320 | 0.000 |
Why?
|
| Injections, Intravenous | 1 | 1990 | 1422 | 0.000 |
Why?
|
| DNA, Viral | 1 | 1993 | 2226 | 0.000 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1993 | 3874 | 0.000 |
Why?
|
| Macaca mulatta | 1 | 1990 | 2375 | 0.000 |
Why?
|
| Aged, 80 and over | 2 | 1999 | 57744 | 0.000 |
Why?
|
| Virus Replication | 1 | 1990 | 2535 | 0.000 |
Why?
|